Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,601-1,650 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__87_B8,2 | Lung | Primary cancer | 3,854 | Tumor/Malignant | 39.7% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__87_B8,3 | Lung | Primary cancer | 3,301 | Tumor/Malignant | 59.6% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__87_B8,4 | Lung | Primary cancer | 3,805 | Tumor/Malignant | 49.0% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__87_B8,5 | Lung | Primary cancer | 3,140 | Tumor/Malignant | 64.2% | 0.97 | 0.14 |
| NSCLC_38242124__IMC__87_B8,6 | Lung | Primary cancer | 2,361 | Tumor/Malignant | 43.6% | 0.89 | 0.33 |
| NSCLC_38242124__IMC__87_B8,7 | Lung | Primary cancer | 2,856 | Tumor/Malignant | 41.3% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__87_B8,8 | Lung | Primary cancer | 2,340 | Tumor/Malignant | 58.5% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__87_B8,9 | Lung | Primary cancer | 2,982 | Tumor/Malignant | 70.6% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__87_C1,10 | Lung | Primary cancer | 4,671 | Tumor/Malignant | 86.6% | 0.98 | 0.05 |
| NSCLC_38242124__IMC__87_C1,11 | Lung | Primary cancer | 2,295 | Tumor/Malignant | 45.8% | 0.90 | 0.28 |
| NSCLC_38242124__IMC__87_C1,12 | Lung | Primary cancer | 715 | Stromal | 30.8% | 0.51 | 0.88 |
| NSCLC_38242124__IMC__87_C1,13 | Lung | Primary cancer | 2,169 | Tumor/Malignant | 38.1% | 0.96 | 0.19 |
| NSCLC_38242124__IMC__87_C1,14 | Lung | Primary cancer | 2,979 | Tumor/Malignant | 45.2% | 0.95 | 0.16 |
| NSCLC_38242124__IMC__87_C1,15 | Lung | Primary cancer | 3,514 | Tumor/Malignant | 48.6% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__87_C1,16 | Lung | Primary cancer | 5,764 | Immune | 92.2% | 0.98 | 0.05 |
| NSCLC_38242124__IMC__87_C1,17 | Lung | Primary cancer | 1,021 | Other | 31.8% | 0.42 | 0.94 |
| NSCLC_38242124__IMC__87_C1,2 | Lung | Primary cancer | 1,044 | Stromal | 35.3% | 0.77 | 0.46 |
| NSCLC_38242124__IMC__87_C1,3 | Lung | Primary cancer | 3,895 | Tumor/Malignant | 67.8% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__87_C1,4 | Lung | Primary cancer | 3,694 | Tumor/Malignant | 35.0% | 0.86 | 0.36 |
| NSCLC_38242124__IMC__87_C1,5 | Lung | Primary cancer | 3,643 | Tumor/Malignant | 71.9% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__87_C1,6 | Lung | Primary cancer | 2,452 | Tumor/Malignant | 39.4% | 0.99 | 0.08 |
| NSCLC_38242124__IMC__87_C1,7 | Lung | Primary cancer | 1,696 | Immune | 30.0% | 0.37 | 0.99 |
| NSCLC_38242124__IMC__87_C1,8 | Lung | Primary cancer | 2,518 | Tumor/Malignant | 36.4% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__87_C2,1 | Lung | Primary cancer | 375 | Stromal | 40.5% | 0.55 | 0.52 |
| NSCLC_38242124__IMC__87_C2,10 | Lung | Primary cancer | 3,909 | Tumor/Malignant | 77.5% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__87_C2,11 | Lung | Primary cancer | 2,149 | Tumor/Malignant | 58.3% | 0.97 | 0.15 |
| NSCLC_38242124__IMC__87_C2,12 | Lung | Primary cancer | 2,290 | Tumor/Malignant | 44.5% | 0.89 | 0.34 |
| NSCLC_38242124__IMC__87_C2,13 | Lung | Primary cancer | 2,176 | Tumor/Malignant | 56.0% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__87_C2,14 | Lung | Primary cancer | 2,940 | Tumor/Malignant | 47.8% | 0.98 | 0.10 |
| NSCLC_38242124__IMC__87_C2,15 | Lung | Primary cancer | 1,413 | Immune | 41.8% | 0.53 | 0.82 |
| NSCLC_38242124__IMC__87_C2,16 | Lung | Primary cancer | 5,954 | Immune | 90.6% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__87_C2,17 | Lung | Primary cancer | 1,544 | Stromal | 34.1% | 0.62 | 0.81 |
| NSCLC_38242124__IMC__87_C2,2 | Lung | Primary cancer | 3,016 | Immune | 26.1% | 0.83 | 0.41 |
| NSCLC_38242124__IMC__87_C2,3 | Lung | Primary cancer | 1,881 | Tumor/Malignant | 51.1% | 0.96 | 0.17 |
| NSCLC_38242124__IMC__87_C2,4 | Lung | Primary cancer | 3,978 | Tumor/Malignant | 39.6% | 0.89 | 0.32 |
| NSCLC_38242124__IMC__87_C2,5 | Lung | Primary cancer | 2,307 | Tumor/Malignant | 52.3% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__87_C2,6 | Lung | Primary cancer | 2,910 | Tumor/Malignant | 30.8% | 0.94 | 0.22 |
| NSCLC_38242124__IMC__87_C2,7 | Lung | Primary cancer | 3,697 | Tumor/Malignant | 38.1% | 0.99 | 0.02 |
| NSCLC_38242124__IMC__87_C2,8 | Lung | Primary cancer | 2,840 | Immune | 31.6% | 0.51 | 0.75 |
| NSCLC_38242124__IMC__87_C2,9 | Lung | Primary cancer | 3,072 | Tumor/Malignant | 31.1% | 0.96 | 0.21 |
| NSCLC_38242124__IMC__87_C3,1 | Lung | Primary cancer | 3,752 | Tumor/Malignant | 42.1% | 0.94 | 0.23 |
| NSCLC_38242124__IMC__87_C3,10 | Lung | Primary cancer | 2,477 | Tumor/Malignant | 50.3% | 0.93 | 0.28 |
| NSCLC_38242124__IMC__87_C3,11 | Lung | Primary cancer | 2,742 | Tumor/Malignant | 63.7% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_C3,12 | Lung | Primary cancer | 3,430 | Tumor/Malignant | 54.5% | 0.95 | 0.19 |
| NSCLC_38242124__IMC__87_C3,13 | Lung | Primary cancer | 885 | Tumor/Malignant | 43.5% | 0.74 | 0.54 |
| NSCLC_38242124__IMC__87_C3,14 | Lung | Primary cancer | 3,208 | Tumor/Malignant | 52.8% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_C3,16 | Lung | Primary cancer | 5,307 | Immune | 81.0% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_C3,2 | Lung | Primary cancer | 1,101 | Tumor/Malignant | 44.2% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__87_C3,3 | Lung | Primary cancer | 3,315 | Tumor/Malignant | 29.6% | 1.00 | 0.06 |
| NSCLC_38242124__IMC__87_C3,4 | Lung | Primary cancer | 3,630 | Tumor/Malignant | 29.9% | 0.83 | 0.51 |